Core Viewpoint - Qingfeng Biotech has completed a multi-million Pre-A round financing, led by Baiyun Fund, to advance its AI+ laboratory automation initiatives, including capacity expansion and the development of AI models [1] Market Status - The laboratory automation market is entering a stable growth phase, with AI becoming a key driver. The global market size is projected to reach approximately $8-8.3 billion in 2024, $9 billion in 2025, and $14-18 billion by 2030, maintaining a compound annual growth rate (CAGR) of 7-9% [2] - In China, the AI-related laboratory market is expected to grow from approximately 15-20 billion RMB in 2024 to 20-25 billion RMB in 2025, and reach 50-60 billion RMB by around 2030, with a CAGR of 15-20% [4] Company Overview - Qingfeng Biotech, established in 2018, focuses on the R&D, production, and sales of life science automation equipment and integrated platforms. The company emphasizes system-level design and platform delivery capabilities rather than just single-device solutions [5] - The OutStanding large-scale automated pipetting workstation integrates high flexibility, modularity, and standardization, supporting multiple life science applications. It has successfully bid for a project valued at nearly 2 million RMB per unit, competing with imported brands [5] AI Integration - Qingfeng Biotech is enhancing its laboratory automation applications by integrating AI capabilities, focusing on the development of BioFlow AI and Supervisor AI models for experimental process management and data-driven optimization [6] - The trend of "AI+ smart laboratories" is evolving from single-point algorithms to core capabilities throughout the entire experimental process, aiming to reduce human error and improve operational efficiency [7] Post-Financing Strategy - The company's development focus is shifting from individual equipment to a systematic construction of "automation platforms + AI capabilities." The financing will be directed towards capacity, algorithms, application centers, and platform capabilities, highlighting the importance of scalable delivery and long-term technological evolution [8]
数千万融资!生命科学自动化创新企业完成Pre-A 轮
思宇MedTech·2026-01-16 03:52